Nevertheless, the insights gained from our structures of the ADAM17/iRhom2 complex, including its regulatory mechanisms, provide a mechanistic basis for the development of future therapeutics to target ADAM17-dependent shedding in inflammatory diseases and cancer. This evidence concerns the gene ADAM17 and cancer.